The active substance marketed under the model code KLK is a pharma-grade urinary kallidinogenase of human urine origin. The material is supplied as a lyophilized powder or loose cake intended for downstream manufacture of parenteral finished products and, with additional formulation development, for oral solid-dose presentations such as tablets, capsules, and granules. The route designations “injectable” and “oral” are not interchangeable for release testing: the injectable grade carries additional controls for sterility, bacterial endotoxins, and subvisible particles, while a non-sterile oral grade is controlled for bioburden and enzyme activity. Because the active substance is a glycoprotein serine protease rather than a small molecule, strength is assigned by biological activity units rather than by mass. The term KLK is a product code and should not be confused with the broader kallikrein-related peptidase gene family. The unit definition and activity reference standard are manufacturer-specific; downstream manufacturers should request the certificate of analysis before formulation.

Production-scale downstream processing of this enzyme shows that shear and pH excursions are the principal process concerns. During ultrafiltration and diafiltration on polyethersulfone cassettes, operation above the vendor-recommended transmembrane pressure can increase high-molecular-weight aggregate content measured by size-exclusion HPLC. Column steps are therefore run at controlled linear flow rates and with stabilizer-containing buffers. The starting material is pooled human urine, which imposes donor eligibility, viral marker testing, and traceability requirements under ICH Q5A. Two orthogonal viral reduction steps are typically expected for injectable-grade biologicals derived from human fluids; the selected unit operations are process-dependent and must be described in the viral validation summary. Because the API is not a defined chemical entity, the process definition and in-process controls carry regulatory weight equal to the final release specification.

What Release Specification Parameters Apply to Glycoprotein Enzyme APIs?

For a biological API of this type, release is not limited to chromatographic purity. The specification should include identity by peptide mapping or immunoelectrophoresis, specific activity, aggregation, moisture, pH of the reconstituted solution, bioburden, and bacterial endotoxins. For injectable grades, sterility and subvisible particulate matter are added. Acceptance limits are derived from the intended dose, route, and stability history. Pharmacopoeial methods are used where applicable; when a monograph is unavailable, the manufacturer validates in-house methods according to ICH Q2(R2) or ICH Q14 as appropriate. The certificate of analysis should report the activity unit definition, the substrate used in the assay, and the reference standard lot. Published data for a fully harmonized international monograph for this specific urinary enzyme are limited; therefore, the applicant should verify the regulatory acceptance of compendial references in the target jurisdiction.

The limit for bacterial endotoxins is calculated from the maximum bolus or infusion dose. A parenteral finished product is considered non-pyrogenic only when the endotoxin load per kilogram of body weight is below the applicable regulatory threshold. For this reason, an API lot can be acceptable for oral development but fail injectable grade if endotoxin or bioburden data are not controlled to parenteral limits. Identity testing for a glycoprotein enzyme is more elaborate than for a synthetic small molecule. Peptide mapping after tryptic digestion provides primary sequence coverage, while immunoblotting or ELISA confirms epitope integrity. Because the enzyme is glycosylated, capillary electrophoresis or HILIC glycan analysis may be used to monitor batch-to-batch glycoform drift, although the acceptance range is often broad. Charge variant analysis by isoelectric focusing or ion-exchange HPLC can reveal sialylation differences that may influence circulating half-life. These tests are not always mandatory for release but are used in process validation and comparability exercises. If the manufacturing process changes, comparability should follow ICH Q5E, and the applicant should demonstrate that the post-change material has comparable activity, impurities, and stability.

For an injectable API, the absence of process-related impurities from human urine is not proven by a single purity value. The impurity profile should include host urine proteins, DNA, process residuals such as chromatographic ligands and detergents, and aggregated or clipped forms. Size-exclusion HPLC is used to quantify high-molecular-weight aggregates, while reversed-phase HPLC or SDS-PAGE is used for clipped forms. The aggregate limit is typically set from clinical experience and process capability, and a conservative specification is required because aggregates can increase immunogenicity. Published data for an internationally harmonized impurity limit for this specific enzyme are limited; the developer should therefore qualify the impurity limits with toxicological and clinical data.

Comparative Source, Glycosylation, and Immunogenicity Boundaries

Urinary kallidinogenase differs from porcine pancreatic kallidinogenase and recombinant tissue kallikrein in source, post-translational modification, impurity profile, and viral safety. The urinary enzyme is of human origin and therefore carries a human glycosylation pattern, but donor-derived raw material introduces variable glycoform distribution and requires viral screening. Porcine pancreatic kallidinogenase carries non-human glycan structures and has a higher probability of interspecies immunogenicity, although its tissue source has different adventitious agent risks. Recombinant tissue kallikrein expressed in CHO cells or another characterized cell bank gives a more consistent glycosylation profile, but the glycan structure depends on the expression host, and process-related impurities shift from host urine proteins to host cell proteins and DNA.

These differences do not establish therapeutic superiority; they affect analytical method selection, immunogenicity monitoring, and the design of viral safety studies. For an injectable dosage form, the urinary source requires documented donor eligibility and two-step viral inactivation or removal. For a recombinant source, the emphasis shifts to cell-bank characterization and host-cell protein clearance. For a porcine pancreatic source, sourcing documentation and porcine adventitious agent testing are the primary concerns. The API purchaser should request the viral validation summary and the pharmacological-toxicological documentation that supports the chosen source. The term KLK should not be interpreted as demonstrating interchangeability with other kallikrein preparations. Activity units such as PNA units or international units are not necessarily identical across suppliers unless the reference standard and substrate assay are explicitly harmonized.

When Formulation Routes Shift Between Injectable and Oral Granule Systems

Although the same enzyme can be discussed for oral and injectable use, the formulation constraints are fundamentally different. For injection, the API is usually filled after sterile filtration and lyophilized with a bulking agent and stabilizer. The lyophilization cycle is designed to keep the product below the collapse temperature during primary drying; the vials are sealed under low-moisture conditions and the residual moisture acceptance limit is set by stability data. Reconstitution with isotonic saline should produce a clear to slightly opalescent solution within the time specified in the finished product label. Subvisible particles, sterility, and endotoxins are release tests for the finished injection, not merely process checks. During aseptic filling, the solution is passed through a sterilizing-grade filter, commonly 0.22 µm, but protein adsorption to the membrane can reduce activity yield. Filter compatibility studies are therefore required. The filling line should be run at low shear, and peristaltic pumps with tight tubing can introduce pulsation and local heating; diaphragm or rotary piston pumps designed for shear-sensitive proteins are preferred. Transfer piping should be sloped and made of low-protein-binding material.

For oral tablets, capsules, or granules, the enzyme is exposed to acid and proteolytic degradation in the gastrointestinal tract. Direct compression and dry granulation are preferred over wet granulation because aqueous granulation can unfold the protein, reduce activity, and increase aggregate content. If a granule is required, low-shear fluid-bed granulation with a controlled inlet dew point and a protective binder solution may be used, but activity recovery after drying and coating must be validated. Enteric coating or an acid-resistant capsule shell is ordinarily required to protect the enzyme from gastric pepsin and low pH. Filling by weight alone is insufficient; hard capsule filling should be controlled by activity units per capsule after accounting for specific activity variation across batches. For tablets, the API is usually blended with a diluent such as mannitol or microcrystalline cellulose, a disintegrant, and a lubricant. Direct compression is preferred because granulation in water may inactivate the enzyme. Dry granulation by roller compaction is acceptable if the compaction force does not generate local temperature close to the denaturation onset. A low-moisture environment is required; effervescent or high-water-activity excipients are not compatible.

For granules intended for oral administration, fluid-bed spraying of a stabilizer solution may be used to apply the enzyme to sugar spheres or mannitol cores. The inlet air temperature and dew point are controlled to avoid denaturation; the product temperature should remain below the collapse or denaturation temperature of the protein. After coating, an enteric film such as methacrylic acid copolymer can be applied to delay release until the small intestine. Release testing should include activity and dissolution in media that simulate the intended gastrointestinal compartment; the assay must be robust to pepsin and bile salts in the dissolution medium. Clinical use of the injectable dosage form has been reported in treatment protocols for acute ischemic cerebral infarction with imaging-confirmed arterial occlusion or cerebral hypoperfusion. The enzyme is used to improve microcirculation, not to lyse fibrin. It is therefore not a substitute for thrombolytic or endovascular recanalization. In some jurisdictions, it is administered as an intravenous infusion once daily for a defined course; the exact dose and duration are set by the finished product label. Because the enzyme can lower blood pressure through kinin-mediated vasodilation, patients with unstable hemodynamics or recent hemorrhage are excluded. The API itself is not approved for direct patient use; it is supplied only to licensed pharmaceutical manufacturers. Oral formulations containing this enzyme have no established pharmacopoeial monograph, and published development data for oral dosage forms are limited.

Stability and processing boundaries for this API are governed by residual moisture, temperature, and shear rather than by chemical stability alone. Lyophilized material should be stored in sealed containers under the conditions stated in the vendor’s stability protocol; cold-chain storage is common because the enzyme is proteinaceous. Container closure integrity should be verified because moisture ingress reduces activity and can promote cake shrinkage. The processing window for dry granulation is constrained by the glass transition or collapse temperature of the formulated mixture; if the powder bed exceeds this boundary during compression or drying, local melting or aggregation may occur and reduce activity yield. Production-scale roller compaction and tablet compression should be monitored for tooling temperature because shear-induced heat can denature the enzyme. Stability studies should follow ICH Q1A(R2) with photostability per ICH Q1B; freeze-thaw stress is relevant to process intermediates, because the final injectable API is lyophilized. Published data for this specific configuration is limited, so formulation-specific forced degradation and process qualification runs are required before scale-up.